➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Baxter
Moodys
Mallinckrodt
AstraZeneca
Express Scripts

Last Updated: August 6, 2020

DrugPatentWatch Database Preview

Deflazacort - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What are the generic sources for deflazacort and what is the scope of patent protection?

Deflazacort is the generic ingredient in one branded drug marketed by Ptc Therap and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

There are three drug master file entries for deflazacort. One supplier is listed for this compound.

Summary for deflazacort
Recent Clinical Trials for deflazacort

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Postgraduate Institute of Medical Education and ResearchPhase 2/Phase 3
Northwestern UniversityPhase 2
Yuzuncu Yıl UniversityPhase 4

See all deflazacort clinical trials

Pharmacology for deflazacort

US Patents and Regulatory Information for deflazacort

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ptc Therap EMFLAZA deflazacort TABLET;ORAL 208684-003 Feb 9, 2017 RX Yes No   Start Trial   Start Trial   Start Trial
Ptc Therap EMFLAZA deflazacort TABLET;ORAL 208684-003 Feb 9, 2017 RX Yes No   Start Trial   Start Trial   Start Trial
Ptc Therap EMFLAZA deflazacort TABLET;ORAL 208684-004 Feb 9, 2017 RX Yes Yes   Start Trial   Start Trial   Start Trial
Ptc Therap EMFLAZA deflazacort SUSPENSION;ORAL 208685-001 Feb 9, 2017 RX Yes Yes   Start Trial   Start Trial   Start Trial
Ptc Therap EMFLAZA deflazacort TABLET;ORAL 208684-002 Feb 9, 2017 RX Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Moodys
Harvard Business School
McKesson
Express Scripts
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.